PMID- 19758240
OWN - NLM
STAT- MEDLINE
DCOM- 20091029
LR  - 20090917
IS  - 1749-6632 (Electronic)
IS  - 0077-8923 (Linking)
VI  - 1173
DP  - 2009 Sep
TI  - Effects of low-molecular-weight heparin on adhesion and vesiculation of 
      phospholipid membranes: a possible mechanism for the treatment of 
      hypercoagulability in antiphospholipid syndrome.
PG  - 874-86
LID - 10.1111/j.1749-6632.2009.04745.x [doi]
AB  - Heparins represent an efficient treatment of acute thrombosis and obstetric 
      complications in antiphospholipid syndrome (APS). Enhanced microvesiculation of 
      cell membranes, as detected by reduced membrane adhesion, can contribute to 
      hypercoagulability in APS. Healthy donor IgG antibodies significantly increased 
      beta2-glycoprotein I (beta2-GPI)-induced membrane adhesion, indicating that IgG 
      antibodies might supplement the role of beta2-GPI in the regulation of membrane 
      microvesiculation in healthy individuals. Anti-beta2-GPI IgG antibodies 
      significantly reduced beta2-GPI-induced membrane adhesion, suggesting a direct 
      role of anti-beta2-GPI antibodies in enhancing membrane microvesiculation in APS. 
      Therapeutic concentration of nadroparin completely restored beta2-GPI-induced 
      membrane adhesion in the presence of anti-beta2-GPI IgG antibodies. A novel 
      anticoagulant mechanism of nadroparin in APS is suggested that supplements its 
      direct effect on the coagulation cascade. Restoration of adhesion between 
      negatively charged membranes in the presence of nadroparin might decrease 
      shedding of microvesicles into the surrounding solution and could thus contribute 
      to the efficacy of heparin treatment in APS.
FAU - Frank, Mojca
AU  - Frank M
AD  - Department of Rheumatology, University Medical Center, Ljubljana, Slovenia.
FAU - Sodin-Semrl, Snezna
AU  - Sodin-Semrl S
FAU - Rozman, Blaz
AU  - Rozman B
FAU - Potocnik, Marko
AU  - Potocnik M
FAU - Kralj-Iglic, Veronika
AU  - Kralj-Iglic V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Anticoagulants)
RN  - 0 (Autoantibodies)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Membrane Lipids)
RN  - 0 (Nadroparin)
RN  - 0 (Phosphatidylserines)
RN  - 0 (Phospholipids)
RN  - 0 (beta 2-Glycoprotein I)
SB  - IM
MH  - Adsorption/drug effects
MH  - Antibodies, Monoclonal/immunology/pharmacology
MH  - Anticoagulants/chemistry/pharmacology
MH  - Antiphospholipid Syndrome/blood/*immunology
MH  - Autoantibodies/immunology/pharmacology
MH  - Blood Coagulation/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Heparin, Low-Molecular-Weight/*chemistry/pharmacology
MH  - Humans
MH  - Immunoglobulin G/immunology/pharmacology
MH  - Membrane Fusion/drug effects
MH  - Membrane Lipids/*chemistry
MH  - Nadroparin/chemistry/pharmacology
MH  - Phosphatidylserines/chemistry
MH  - Phospholipids/*chemistry
MH  - beta 2-Glycoprotein I/chemistry/immunology/pharmacology
EDAT- 2009/09/18 06:00
MHDA- 2009/10/30 06:00
CRDT- 2009/09/18 06:00
PHST- 2009/09/18 06:00 [entrez]
PHST- 2009/09/18 06:00 [pubmed]
PHST- 2009/10/30 06:00 [medline]
AID - NYAS4745 [pii]
AID - 10.1111/j.1749-6632.2009.04745.x [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2009 Sep;1173:874-86. doi: 10.1111/j.1749-6632.2009.04745.x.